Cercare Medical is excited to join the 19th Annual Meeting of the American Society of Functional Neuroradiology (ASFNR), taking place 9–12 October 2026, in Newport Beach, California.
Cercare Medical continues to support the advancement of neuroimaging. This year, we are happy to introduce the next evolution of our portfolio, the Cercare Medical Cone-Beam CT Perfusion.
Cone-Beam CT (CBCT) Perfusion brings CT-quality perfusion imaging - along with Cercare Medical’s unique oxygen-metabolism biomarkers into the angio suite using the standard C-arm systems already in place. For the first time, interventional teams can assess tissue health and viability in real time, at the point of treatment.
Discover how Cone-Beam CT Perfusion can be integrated with syngo DynaCT Multiphase on the Siemens Healthineers ARTIS icono family. The solution extends the capabilities of Cercare Medical Neurosuite into the angio suite, providing advanced perfusion imaging to support clinicians during image-guided stroke treatment.
We will be showcasing Cercare Medical Neurosuite (CMN), our flagship solution for advanced perfusion imaging and quantitative analysis across CT, CBCT, and MR.
CMN supports efficient stroke workflows through fully automated perfusion processing, providing standardized and reproducible maps and quantitative biomarkers, including:Â CBF, CBV, MTT, OEF, CMROâ‚‚, and CTH.
CMN allows full Integration across the clinical workflow, from emergency imaging to the angio suite.
Visit us for live demonstrations of our latest perfusion and AI imaging solutions. Our team will be available throughout the event to discuss your clinical or research needs.
See you in California!
Cercare Medical is a provider of advanced perfusion imaging solutions. With fully automated and multi-vendor compatible software for CT, CBCT, and MRI perfusion imaging post-processing, we are committed to delivering cutting-edge technology that enhances patient care and advances medical diagnostics across various neurological conditions, including Stroke, Oncology, Alzheimer's, Dementia, and COVID-19. Our proprietary biomarkers allow for better, more precise imaging maps, improving decision-making in critical care and enhancing neuroimaging. This innovative technology has led to widespread adoption by leading hospitals and clinics around the world.